3-Methyladenine (3-MA)

Catalog No.S2767 Synonyms: NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.

Size Price Stock Quantity  
USD 70 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 41 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Targets
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr1SW9RO22P MV:ybC=> NEHsSlJFVVOR NWe2fY9{emWmdXPld{Boem:5dHigbY5pcWKrdH;yfUBm\m[nY4Sgc4YhSkSPQx?= MnjoNlU4OTZ3NkG=
A549  MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLWWGNtO22P NV32NHpiOmh? MnHsSG1UVw>? MVry[YR2[2W|IHfyc5d1cCCrbnjpZol1d3K7IHXm[oVkfCCxZjDCSG1E MnLmNlU4OTZ3NkG=
95D M2nmVWFxd3C2b4Ppd{BCe3OjeR?= M4HSWVVuVQ>? MmfPNog> M3HCTWROW09? NFTTTVFqdmirYnn0d{BDTE2FLXnu[JVk\WRiYYDvdJRwfGmlIHPlcIwh\GWjdHi= NIjvW5IzPTdzNkW2NS=>
A549  M1TYfGFxd3C2b4Ppd{BCe3OjeR?= MWS1cW0> M{nPXVJp MlKwSG1UVw>? NF[xbGxqdmirYnn0d{BDTE2FLXnu[JVk\WRiYYDvdJRwfGmlIHPlcIwh\GWjdHi= MVGyOVcyPjV4MR?=
NBL-W-S  M4\lTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfjWYIydU1? MXO2bC=> NHvDN3pmdmijbnPld{BISU6WLU[xJJRwgGmlaYT5 NEnlW5IzPTN{M{KyNi=>
NBL-W-S  M4jCPWFxd3C2b4Ppd{BCe3OjeR?= NHnJdnIydU1? M4D4[lZp M4TCN4lv[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JGdCVlRvNkG= Mk\jNlU{OjN{MkK=
A2780cp  NYDLSGJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:xcW0> M{Px[FFp M{fRdYlv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp NX;DU4xNOjV|MkK2PVQ>
A549  MmX5SpVv[3Srb36gRZN{[Xl? NEfUWZo2dU1? MUSybC=> MWXzeZBxemW|c3XzJHNRSyCrbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBNSzNvSVm= M{LBPFI2Ojh3NkK4
H157 NELhd4ZHfW6ldHnvckBCe3OjeR?= MYK1cW0> NGHl[mczcA>? M1\TUJN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=> NWfIUXJ1OjV{OEW2Nlg>
MDR MlTORZBweHSxc3nzJGF{e2G7 MlP1NVBuVQ>? M172[VZp M3jvTJN1emWwZ4To[Y5{KHSqZTDwc5dmeiCxZjDhcpRq[2GwY3XyJIRzfWe| M1mwW|I2ODF7N{Cx
HT-29  M122R2Fxd3C2b4Ppd{BCe3OjeR?= MYexcW0> NGTFWpU1QGh? MofCSG1UVw>? NVXXXZhL\W6qYX7j[ZMh[m:{dHX6c41q[i2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? MkjUNlQ5PDJzNUi=
Microglia  MWDBdI9xfG:|aYOgRZN{[Xl? MmD1OY1O NUnqOJlOOjSq NV\BN5hQ\GWlcnXhd4V{KGi7cH;4bYEucW6mdXPl[EBk\WyuIHTlZZRp M1rTNlI1QDF6NkCx
A2780cp MoXhRZBweHSxc3nzJGF{e2G7 MoW5Nk42dU1? M3qyUlFp NYn4T5hC\GSKMl:= NYrJemJ1\W6qYX7j[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? MmXINlQ5OTd7NE[=
HepG2 M3zpZmZ2dmO2aX;uJGF{e2G7 MUm1cW0> M{PxN|Rp MXvpcoNz\WG|ZYOgTGwhemWuZXHz[S=> MVqyOFcyOzV6Nx?=
A549 NGPqUnNCeG:ydH;zbZMhSXO|YYm= Ml\nOY1O MYm0PIg> MmPu[IVkemWjc3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGxiZHXheIgh[W6mIHX4dJJme3Orb36gcIV3\Wy|IH;mJINie3Cjc3WtN{whSmWlbHnuMVEh[W6mIFzDN{1KUQ>? NIDQd5UzPDdyNkOwNy=>
U2OS NWq5Xo5sSXCxcITvd4l{KEG|c3H5 NYTXdJNNOTCvTR?= M3zwTVI1cA>? M4DUfolvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDv[kB1cGViVULPV{Bk\WyuczDpcoR2[2WmIHL5JGRwgA>? M{jyRlI1PjN7MEGz
Saos-2 MXrBdI9xfG:|aYOgRZN{[Xl? M1S3dlExdU1? NIL3SXQzPGh? M1nT[4lvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDv[kB1cGViVULPV{Bk\WyuczDpcoR2[2WmIHL5JGRwgA>? MnnKNlQ3OzlyMUO=
A549 M2fhO2Fxd3C2b4Ppd{BCe3OjeR?= NX;pN|VXOTCvTR?= MlG5OFhp NWfSVYtO[WOlZXzldoF1\XNidHjlJJJm\HWldHnvckBw\iClZXzsJJZq[WKrbHn0fUBqdmS3Y3XkJIJ6KFCWWB?= NHqxdVYzPDZ{NkeyNi=>
HCT116  Ml;QRZBweHSxc3nzJGF{e2G7 M3SyRVVuVQ>? M4HpeFI1cA>? M1;2dIVvcGGwY3XzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDhdIlo\W6rbh?= MXmyOFYzPjV{Mh?=
HGC-27 NFm4R5hHfW6ldHnvckBCe3OjeR?= MYixNI1O MWGxbC=> NFHWbWZqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJkhdG:|czDifUBTSURyMEGgc5IhVUtvMkKwOi=> M4PNUlI1PDF4M{S5
U2OS  MWHGeY5kfGmxbjDBd5NigQ>? NX7zVVBVOC53L{HtUS=> NWXzdopEPDiq MlLhbY5lfWOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> M4HnW|I1OzV6M{Sy
MG-63 NGXy[GtHfW6ldHnvckBCe3OjeR?= M4m3blAvPS9zbV2= NXHr[oFHPDiq NGi5UmlqdmS3Y3XzJJNidGmwb335Z4lvNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? NXO1dYk1OjR|NUizOFI>
MG-63 MojhRZBweHSxc3nzJGF{e2G7 NVjyVo5MOC53L{HtUS=> M3OzOVMzcA>? MYDlcohidmOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxiYYDvdJRwe2m| MmD3NlQ{PTh|NEK=
MG-63 MYfBdI9xfG:|aYOgRZN{[Xl? M1fkdlExdU1? MlLrNVJp NGSycVVmdmijbnPld{BFWC2rbnT1Z4VlKGGyb4D0c5Nqew>? MkPENlQ{PTh|MEG=
NTUB1 NILibopCeG:ydH;zbZMhSXO|YYm= MlnUOY1O M3PGXFEvPWh? NX;DVnJMeG:2ZX70bYF1\XNiY3Xs[YNwgGmkLXnu[JVk\WRiYYDvdJRwe2m| NVPpe45DOjR|NEmxO|Y>
T24 MmD5RZBweHSxc3nzJGF{e2G7 M2myfFVuVQ>? NVLxWWNHOS53aB?= MXrwc5RmdnSrYYTld{Bk\WynY3;4bYIucW6mdXPl[EBieG:ydH;zbZM> M{SwOlI1OzR7MUe2
SGC-7901  NY\NWnpxSXCxcITvd4l{KEG|c3H5 M2PGS|JuVQ>? M4fORVFp MljFbY5kemWjc3XzJGNCNTRiaX7keYNm\CCjcH;weI9{cXN? MojyNlQ{OjF|NEC=
SMMC-7721 Mo[5RZBweHSxc3nzJGF{e2G7 M17qV|JuVQ>? M1GzdVFp MVHpcoNz\WG|ZYOgR2EuPCCrbnT1Z4VlKGGyb4D0c5Nqew>? M1XQW|I1OzJzM{Sw
ECSCs  NELuS49CeG:ydH;zbZMhSXO|YYm= MnPHNVBuVQ>? M3PydVRp NWnk[lZE\GWlcnXhd4V{KHKjcHHtfYNqdi22cnXheIVlKGGyb4D0c5Nqew>? NGDhUm0zPDNzOUGwPS=>
MCF-7  NEW1dm5HfW6ldHnvckBCe3OjeR?= MoH3NVBuVQ>? MUCyOIg> NW\IbVJucW6qaXLpeJMhfGinIHH1eI9xcGGpeTDpcoR2[2WmIHL5JINp\W2xdHjldoFxgSCmcoXndy=> MY[yOFMyPTV5OB?=
UOK257 NV7QSXRlSXCxcITvd4l{KEG|c3H5 MnXBOY1O NFnSS2w{cA>? NVfMNJMx\W6qYX7j[ZMheGGlbHn0ZZhmdC2vZXTpZZRm\CCjcH;weI9{cXQEoB?= NX7UcHFCOjR|MEW2NFQ>
ACHN-5968 NVTMPZM{SXCxcITvd4l{KEG|c3H5 MXi1cW0> NEHoSZA{cA>? M4rtTYVvcGGwY3XzJJBi[2yrdHH4[YwudWWmaXH0[YQh[XCxcITvd4l{yqB? MlXLNlQ{ODV4MES=
Huh7 NYfpTnN{SXCxcITvd4l{KEG|c3H5 NFvGT5EzdU1? NWrEWHQ{OTKq NXzKc2VDTE2VTx?= M1P0[YlvcGmkaYTzJGFbTDhyNUWtbY5lfWOnZDDj[YxtKGSnYYTo M2nUTFI1Ojl5M{Cw
Hep3B NHSycoxCeG:ydH;zbZMhSXO|YYm= NUfCZYFrOm2P NYi1R4VEOTKq Ml\GSG1UVw>? M4\QVolvcGmkaYTzJGFbTDhyNUWtbY5lfWOnZDDj[YxtKGSnYYTo NVK2dIZnOjR{OUezNFA>
RKO MV3GeY5kfGmxbjDBd5NigQ>? MlfNNo1O Mn7CNYg> MXLEUXNQ MXzlcohidmOnczDj[YxtKGSnYYToJIJ6KGenbHThcoFugWOrbh?= NFzMPY4zPDJ7MUe3Oy=>
HepG2 E47 MVXGeY5kfGmxbjDBd5NigQ>? NXLaO|ZGOi53bV2= MYq0PIg> NHTnV2hqdmO{ZXHz[ZMhfGinIITvfIlkcXS7IH;mJGFCNCCEU1:sJIFv\CCFQ3y0 MYiyOFI4Ozd|OB?=
LoVo  NFztbGhCeG:ydH;zbZMhSXO|YYm= M3LQOFVuVQ>? M{fXO|Q5cA>? NVjBV4Vi\W6qYX7j[ZMhTEODLXnu[JVk\WRiYYDvdJRwe2m|Lh?= NEnLRXUzPDJyMUixNi=>
WiDr NHLUUXJHfW6ldHnvckBCe3OjeR?= NVjLU3JlOTCvTR?= MlXBNYg> NIXpUo1qdmirYnn0d{BRS0KOLXnu[JVk\WRiTFOzJGlKKGW6cILld5Nqd25? NUm3VG5kOjRzOUC0PFk>
H1299  NHvaSoNHfW6ldHnvckBCe3OjeR?= NV;UVVF7OTCvTR?= M2Dld|Rp MmTvbY5kemWjc3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> MonJNlQyPzN{MEi=
H460 MknrSpVv[3Srb36gRZN{[Xl? MVKxNI1O NWjr[WVkPGh? M1yxbIlv[3KnYYPld{BkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp M4rDSVI1OTd|MkC4
A549 MVrGeY5kfGmxbjDBd5NigQ>? NXfmOndoOTCvTR?= MlnNOIg> MoftbY5pcWKrdIOgZZV1d3CqYXf5JIlv\HWlZXSgZpkhcXK{YXTpZZRqd25? MXWyOFE1Ojd|NR?=
Hep3B NXTmTVhqSXCxcITvd4l{KEG|c3H5 NEf3UWE2dU1? NWDFU3E6OjSq MmTHZZR1\W63YYTld{BVVkZvzsGgdJJwfGWldHnvckBi\2GrboP0JJNmenWvIIP0ZZJ3[XSrb36tcYVlcWG2ZXSgZZBweHSxc3nz NHnleHIzPDB4Nk[5Ny=>
SMMC-7721 NFnTVGFCeG:ydH;zbZMhSXO|YYm= NWP6NZkzPW2P M3za[lI1cA>? M3LFPIF1fGWwdXH0[ZMhXE6ILd8xJJBzd3SnY4Tpc44h[WejaX7zeEB{\XK3bTDzeIFzfmG2aX;uMY1m\GmjdHXkJIFxd3C2b4Ppdy=> NXfRfmJIOjRyNk[2PVM>
HO8910 M4HNeWFxd3C2b4Ppd{BCe3OjeR?= MkjTNVBuVQ>? MlW0NVJp MnPY[Y5p[W6lZYOgRlE6NWmwZIXj[YQh[XCxcITvd4k> M4e4O|I{QTh|NkGw
MCF7 NFnxZ|FHfW6ldHnvckBCe3OjeR?= MWK1cW0> M2DGWFI1cA>? MoK0bY5kemWjc3XzJGN2VyCrbnT1Z4VlKGOnbHyg[IVifGh? NYXkR2hHOjN7NkK2Nlk>
HONE-1  MWPGeY5kfGmxbjDBd5NigQ>? MY[1cW0> MWSxbC=> MULy[ZBz\XO|ZYOgOpIudWWmaXH0[YQhWk:VIIDyc4R2[3Srb36= MoHENlM5QTJ|NUi=
HeLa Mn7uSpVv[3Srb36gRZN{[Xl? MlvENVBuVQ>? MkLONog> M3vZfpN2eHC{ZYPz[ZMhVEN|IFnJJIV5eHKnc4Ppd49v NYLoPGhJOjN6NkS3N|g>
HepG2 M{DC[GZ2dmO2aX;uJGF{e2G7 NWTTSJQ5OTCvTR?= MWKyOIg> NX;jXmJrcW6qaXLpeJMhe2mWSVfBVk0h[W6mIFjCV3MucW6mdXPl[EBifXSxcHjh[5k> NWrjeYI6OjN6MUewOFA>
SH-SY5Y MUPGeY5kfGmxbjDBd5NigQ>? NXjicmxLOW2P MkKxNlRp M1zWUIlvcGmkaYTzJJRp\SCjdYTvdIhi\3liaX7keYNm\CCkeTDUU2NR MYmyN|c1OzF2OB?=
SH-SY5Y NXPBdWJGSXCxcITvd4l{KEG|c3H5 Mo\aOY1O NEPoRY0ycA>? MnLmZYJwdGm|aHXzJINmdGG|dILvcEBv\XW{b4Dyc5Rm[3SrdnWg[YZn\WO2 NGTU[pUzOzZzOUO5OS=>
PC12  M3LybGZ2dmO2aX;uJGF{e2G7 MVOxNI1O MoryNlRp M{P3cpdifGW{ NX7W[4VlyqCrbnjpZol1eyClaIntc5RzgXC|aX6tcIls\SCycn;0[YF{d22jbDDhZ5Rqfmm2eT6= MkjmNlM3ODN7N{m=
OV2008 MV7BdI9xfG:|aYOgRZN{[Xl? MnnROY1O Mn\kNlRp NYXZVJNM[2:wdnXyeJMhTlS\N{KwJJdqfGhiQ1TEVEBqdnSxIHHuJIFl\Gm2aY\lJIVn\mWldDD0c5diemS|IHvpcIxqdmdib4\hdolidiClYX7j[ZIh[2WubIO= MoDKNlM2QTJ{OEG=
A2780 NYDHPGpDSXCxcITvd4l{KEG|c3H5 NV;BWWVyPW2P M1LNcFI1cA>? MlnWZ49vfmW{dIOgSnR[PzJyIIfpeIghS0SGUDDpcpRwKGGwIHHk[Il1cX[nIHXm[oVkfCC2b4fhdoR{KGurbHzpcochd3[jcnnhckBk[W6lZYKgZ4VtdHN? MX6yN|U6OjJ6MR?=
Saos-2  M1nleWFxd3C2b4Ppd{BCe3OjeR?= M2DCRlFuVQ>? M2W0SVk3cA>? MW\pcoNz\WG|ZYOgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KFCFWB?= NFnOZ4EzOzV4M{G3NS=>
1321N1 NV:yS3VXS3m2b4TvfIlkcXS7IFHzd4F6 NEDvTXI2dU1? NVTUWphYOjSq NELRdllxem:2ZXP0d{Bk\WyuIHHnZYlve3RiUFPOMYlv\HWlZXSgeI95cWOrdIm= MkPuNlM2OjV{NkW=
SH-SY5Y MmnNR5l1d3SxeHnjbZR6KEG|c3H5 Ml;uOY1O M3HtWFI1cA>? NGm1OGZqdmO{ZXHz[ZMhWEOQIITvfIlkcXS7 NGDmd2YzOzV{NUK2OS=>
HT-29  MV7GeY5kfGmxbjDBd5NigQ>? NH3UNHIydU1? NHHqSI81QC97Nni= NYnwUlhMcW6qaXLpeJMhSU2SSzDpcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> NWTOVXVROjN3MEiyO|I>
OR6 MkPTSpVv[3Srb36gRZN{[Xl? NHywXY8yOG2P MoW5O|Jp M4nLepN2eHC{ZYPz[ZMhUEOYIILldIxq[2G2aX;uJIFv\CCob4LtZZRqd25ib3[gZZV1d3CqYXfvd49u\XN? M1zXdFI{Ozl3OEe1
Hela  MXjGeY5kfGmxbjDBd5NigQ>? MYW1cW0> NXrYZlFFOjSq NGjSO2xqdmirYnn0d{B{fGG{dnH0bY9vNWmwZIXj[YQh[XW2b4DoZYd6 NFiw[FUzOzN7NU[3PS=>
MCF-7  NHi4WmtHfW6ldHnvckBCe3OjeR?= M33pcFVuVQ>? MVmyOIg> NULwTlFQcW6qaXLpeJMhe3Sjco\heIlwdi2rbnT1Z4VlKGG3dH;wbIFogQ>? MUmyN|M6PTZ5OR?=
HUVECs NWTJe2JiTnWwY4Tpc44hSXO|YYm= NX3JSXpYO22P Mof3NlRp MX3icI9kc3NidHjlJJBzd3SnY4TpeoUh\W[oZXP0JI9nKHKnc4\ldoF1em:uIHL5JIlvcGmkaYTpcoch[XW2b4DoZYd6 MkfLNlM{PTh7Mki=
T24 MkjtSpVv[3Srb36gRZN{[Xl? M4HVclExdU1? M2fGUVFp MVry[YR2[2W|IITo[UBkdGWjdnHn[UBw\iCOQ{OgZYZ1\XJiYnHpZ4FtcW5idILlZZRu\W62 NGPMZ3YzOzN3NEC4NC=>
U251MG  NEnQc2lHfW6ldHnvckBCe3OjeR?= NYDO[2tiO22P MkDlNYg> NHmyeFJ{fXCycnXzd4V{KEyFMz3JTUBxem:2ZXnuJIV5eHKnc4Ppc44> M1vGTlI{OzN6NkG4
GTL-16  MnTxRZBweHSxc3nzJGF{e2G7 MUi1cW0> M{i0TlI1cA>? NHuxV3pz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHzJINwdXCjcnXkJJRwKGOnbHzzJJRz\WG2ZXSge4l1cCCPRWSgbY5pcWKrdH;ydy=> MVmyN|MyOzR7MB?=
T-47D MWXGeY5kfGmxbjDBd5NigQ>? M{m0U|ExdU1? NXr0NoVkOmh? MVTpcohq[mm2czDheZRweGijZ4mgdJJw[2W|czDhcoQhcW6lcnXhd4V{KHKjcHHtfYNqdiCrbnT1Z4VlKGGyb4D0c5Nqew>? MnqwNlM{ODByMk[=
PaCa44 M3PHXmFxd3C2b4Ppd{BCe3OjeR?= NHHxW5QzNjWvTR?= NH3welgycA>? MUDy[YR2[2W|wrDn[Y5qeGmwLX3l[IlifGWmIHHwc5B1d3Orcx?= M3;qPVI{OTJ2MUGy
MDA-MB231 Mn\tSpVv[3Srb36gRZN{[Xl? NGXrdWg2dU1? NYnYWoZqOWh? NHfTeZpqdmO{ZXHz[ZMhemW|dnXyZZRzd2xvbXXkbYF1\WRiY3HzdIF{\SCjY4TpeoF1cW:wIHHu[EBk\WyuIHTlZZRp NITXNlMzOzB6OEi1NC=>
HeLa NYPEenNKSXCxcITvd4l{KEG|c3H5 MX:xNI1O MYiybC=> Mnvi[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHPvMZRz\WG2bXXueEB4cXSqIGDFTS=> MXmyN|AxODF|NR?=
SK-HEP-1 NEPjNFdCeG:ydH;zbZMhSXO|YYm= NYnlPItsOTCvTR?= NVuyVld[OWh? MnjvdJJwfGWldIOgZYdicW6|dDDheZRweGijZ4mgZY5lKGmwZIXj[ZMh[XCxcITvd4l{KGmwIHL1[oFtcW5vdILlZZRm\CClZXzsdy=> NE\Te20zOjh3OE[0PS=>
HepG2 MmC3RZBweHSxc3nzJGF{e2G7 M1fxWVNuVQ>? MX[1bC=> MVzy[YR2[2W|IHPlcIwh[XCxcITvd4l{KGmwZIXj[YQh[nliUVTz NIradFEzOjh|NkW5OS=>
MCF-7  M2joemZ2dmO2aX;uJGF{e2G7 M1rr[lJuVQ>? MnrHNlRp MkO3bY5pcWKrdIOgZZV1d3CqYXf5JIlv\HWlZXSgZpkhXE4EoB?= MViyOFk4ODZ5Nh?=
MDA-MB-231 NH;tV2tHfW6ldHnvckBCe3OjeR?= M3\T[lJuVQ>? NHfXPFkzPGh? MlHObY5pcWKrdIOgZZV1d3CqYXf5JIlv\HWlZXSgZpkhXE4EoB?= MonhNlQ6PzB4N{[=
MCF-7  M13JR2Z2dmO2aX;uJGF{e2G7 MWWycW0> MknrOFhp NYXMdG5EeHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq MnHWNlQ6PzB4N{[=
MDA-MB-231 NHztcHBHfW6ldHnvckBCe3OjeR?= M{SyTFJuVQ>? NH;CbJE1QGh? NHnWPGlxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? Mof3NlQ6PzB4N{[=
PANC-1  M1HMUGFxd3C2b4Ppd{BCe3OjeR?= MXuxcW0> MYG0PIg> NILWV3NFVVOR NWOzRmdP\W6qYX7j[ZMh[m:{dHX6c41q[i2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? NVSwNnFJOjR6NEKxOVg>
MDA-MB 231 M4Lw[2Fxd3C2b4Ppd{BCe3OjeR?= MnzxOY1O MYSwMlVp NVe4XGpWdW:mdXzheIV{KFSxY3;tbY7DtsLiaX7keYNm\CCjcH;weI9{cXN? MlnpNlQ5OzB5OEG=
Microglia  NXvIXpo1SXCxcITvd4l{KEG|c3H5 Ml7qOY1O M4LJRlI1cA>? Mlvn[IVkemWjc3XzJIh6eG:6aXGtbY5lfWOnZDDj[YxtKGSnYYTo MnPnNlQ5OTh4MEG=
A2780cp MUHBdI9xfG:|aYOgRZN{[Xl? M1fHS|IvPW2P M4CzOFFp NG\IcFNl\Eh{Tx?= M{TQWYVvcGGwY3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NIfWZlgzPDhzN{m0Oi=>
HepG2 NHHLWXNHfW6ldHnvckBCe3OjeR?= M3HKRlVuVQ>? NYfZVmhsPGh? NWXtXXBGcW6lcnXhd4V{KGOnbHz1cIFzKGyndnXsd{Bw\iCKTNMg M4LNOlI1PzF|NUi3
U2OS M3v6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33UclExdU1? NGDPO|czPGh? NYnxSZBxcW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJIlv\HWlZXSgZpkhTG:6 NHXIb5ozPDZ|OUCxNy=>
HCT116 NHrvb3RCeG:ydH;zbZMhSXO|YYm= NWHtZnhCPW2P MX[yOIg> NEDUO2JFVVOR NH7INVFmdmijbnPld{BieGmpZX7pck1qdmS3Y3XkJINmdGxiZHXheIg> NGr1U|YzPDZ{NkWyNi=>
MCF-7  M2C3ZWFxd3C2b4Ppd{BCe3OjeR?= M2jab|AvOW2P NGnpSYY3cA>? MV3lcohidmOnczDzbZJ1cW6xbD3pcoR2[2WmIHHwc5B1d3Orcx?= MV2yNlc2OTl6OR?=
PC-3  MoPzRZBweHSxc3nzJGF{e2G7 NGjYcYEzdU1? NIXtd5QzcA>? M2\Hdolv[3KnYYPld{BQWklvaX7keYNm\CClZXzsJIRm[XSq NHLY[ZQzOjd2NUW4NC=>
U251  MXfBdI9xfG:|aYOgRZN{[Xl? MVe1cW0> Mof4NlRp NETBT4RqdmO{ZXHz[ZMhWzFvaX7keYNm\CClZXzsJIRm[XSq NHzkcY4zOjV5OUe4PC=>
HeLa  NXn4cox1SXCxcITvd4l{KEG|c3H5 NWfOTWdnPW2P MlTmNlRp MX7pcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHPlcIwh\GWjdHi= NHjwO2kzOjV2NUGyPC=>
A549 NUTzT3F1TnWwY4Tpc44hSXO|YYm= Mm[xNE4ydU1? MlL4NlRp M1\rOJN2eHC{ZYPz[ZMhW1VzMUK3OE1qdmS3Y3XkJINmdGxiZHXheIg> NVflbIR[OjJ2Nk[5OlA>
pDCs MlPuSpVv[3Srb36gRZN{[Xl? MVmxNI1O NHHldVAxNjWq NGnyVI3DqHKnZIXj[ZMhfGinIHnu[JVkfGmxbjDv[kBKTk5vzsGgZpkhe3OUTlG0NC=> M3THNlIzOzl4NUm5
BGC-823 MVvGeY5kfGmxbjDBd5NigQ>? MVS1cW0> NF\ieHUzcA>? M1rjNolvcGmkaYTzJJRp\SC{YYTlJI9nKGG3dH;wbIFocWNiY3XscJM> NE\YemwzOjN{MkG1Ni=>
U937 NGiydY1HfW6ldHnvckBCe3OjeR?= MVWycW0> MVWxNog> MY\k[YNz\WG|ZYOgeIhmKGG3dH;wbIFogSC{YYTpc:Kh MmjENlIyPTVzNUC=
Marc-145 MXrGeY5kfGmxbjDBd5NigQ>? M3jpW|VuVQ>? M4TRR|EzNzJ2L{O2bC=> Mo\5doVlfWOnczD0bIUhWFKUU2[geIl1\XK|IHHu[EB1cGVicILveIVqdiCneIDy[ZN{cW:w NXTKb4ZxOjJzMUm5NFA>
HBx  MUXBdI9xfG:|aYOgRZN{[Xl? NEOxWWMyOG2P NXjHOJo3PDiq NEfsVm9FVVOR M{nuNIlv[3KnYYPld{Bk\WyuIHTlZZRp NXzI[4xNOjJyMkCwO|g>
MCF-7 MojvSpVv[3Srb36gRZN{[Xl? MkPLNVBuVQ>? M4DMd|Q5cA>? NUjCNVhi[myxY3vzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KGKxcoTlfo9ucWJ? M2fMcVIyQTNzOUO3
RMPI8226  M4PSeWZ2dmO2aX;uJGF{e2G7 MYC1cW0> MX:xbC=> NF3SbnN{fXCycnXzd4V{KHSqZTDs[ZZmdCCxZjDheZRweGijZ4mgeY5l\XJiboX0dolmdnRiZHXwcIV1cW:w MU[yNVkyPTZ{MB?=
PC12/TetOn NUXBbIQ{TnWwY4Tpc44hSXO|YYm= M12yV|AvOS9zbV2= NFGyVlcyQGh? NIO4SIpt\WGmczD0c{DPuS2|eX6oW3QqKGGlY4XteYxifGmxbjygeI95cWOrdImsJIFv\CCxbHnnc41meiCob4LtZZRqd28EoB?= M3L6c|IyQTB4NkW5
HeLa  Mor5R5l1d3SxeHnjbZR6KEG|c3H5 MW[ycW0> M3HCOVI1cA>? MlfibY5pcWKrdHXzJJRp\SCleYTveI95cWOrdImgc4Yhe2muaXLpcolvKHSxIFjlUIEh[2WubIOu NETuW4IzOTh5NUO4OS=>
Jurkat NIPJXVZHfW6ldHnvckBCe3OjeR?= NVnscolyOTCvTR?= M{KwdVFp MnvI[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEOy2LSTDhcoQhfGinIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= MVWyNVg3PDB|Nx?=
K562 MlzxSpVv[3Srb36gRZN{[Xl? MYixNI1O MXGxbC=> NFLCSm5l\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVEN|LVnJJIFv\CC2aHWg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz MUCyNVg3PDB|Nx?=
Nara-H NX\yXmZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWC1cW0> M3vuO|Q5cA>? NFPxN29mdmijbnPld{B1\W2|aYLvcIlufXOvZXTpZZRm\CC|dYDwdoV{e2mxbjDv[kBP[XKjLVigZ4VtdCCycn;sbYZmemG2aX;u NHXoOIEzOThyNUCzNy=>
HUVECs NYOwdnlTTnWwY4Tpc44hSXO|YYm= NHXte2kyOG2P NHX6d5QxNjWq NXj6[oQz\GWlcnXhd4V{KHSqZTDBS2UuSlODaX7keYNm\CCjdYTvdIhi\3libHX2[S=> MVGyNVQ3QDV7Mh?=
HepG2 NFfo[YlCeG:ydH;zbZMhSXO|YYm= NXnZWHhGOm2P NEDyZY4ycA>? M{T4U4VvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJINmdGxiZHXheIg> MlL4NlE1PTN4OUG=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; 

PubMed: 29296191     


Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells.

caspase-3 / caspase-9 / PARP; 

PubMed: 25891159     


EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase.

VEGF; 

PubMed: 25891159     


Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor.

APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; 

PubMed: 26316755     


Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.

29296191 25891159 26316755
Immunofluorescence
LC3 / Hif-α / COX2; 

PubMed: 29039446     


Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.

29039446
Growth inhibition assay
Cell viability; 

PubMed: 26934124     


KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.

26934124
In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
+ Expand

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
+ Expand
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
+ Expand
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Formulation: Saline
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • Answer:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products5

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID